Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects.

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res (2014) 0.95

Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace. Adolesc Psychiatry (Hilversum) (2013) 0.89

Neoclerodanes as atypical opioid receptor ligands. J Med Chem (2013) 0.85

Drug models of schizophrenia. Ther Adv Psychopharmacol (2015) 0.82

Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans. Int J Neuropsychopharmacol (2015) 0.82

Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse. Adv Pharmacol (2014) 0.81

Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans. J Psychopharmacol (2016) 0.80

Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol (2016) 0.78

Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Front Pharmacol (2015) 0.78

Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat. Psychopharmacology (Berl) (2014) 0.77

Salvinorin A decreases mortality and improves neurological outcome in a neonatal mouse hypoxia model. Transl Perioper Pain Med (2014) 0.77

Salvinorin A analogues PR-37 and PR-38 attenuate compound 48/80-induced itch responses in mice. Br J Pharmacol (2015) 0.77

Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability. J Med Chem (2017) 0.76

Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans. Int J Neuropsychopharmacol (2016) 0.75

Cardiovascular Disease Chemogenomics Knowledgebase-guided Target Identification and Drug Synergy Mechanism Study of an Herbal Formula. Sci Rep (2016) 0.75

Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET. Neuropsychopharmacology (2015) 0.75

Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study. J Mol Graph Model (2016) 0.75

Salvinorin A: A Mini Review of Physical and Chemical Properties Affecting Its Translation from Research to Clinical Applications in Humans. Transl Perioper Pain Med (2014) 0.75

The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and β-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects. Psychopharmacology (Berl) (2017) 0.75

The Brief Symptom Inventory: an introductory report. Psychol Med (1983) 22.83

Pragmatics of measuring recognition memory: applications to dementia and amnesia. J Exp Psychol Gen (1988) 7.42

Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A (2002) 4.34

Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther (1971) 4.30

Anatomy of CNS opioid receptors. Trends Neurosci (1988) 2.82

Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther (2005) 2.66

Reward processing by the opioid system in the brain. Physiol Rev (2009) 2.46

Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol (1994) 2.28

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) (2006) 2.07

The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat Neurosci (1998) 2.01

Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther (2004) 1.89

Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend (2006) 1.52

Interactions between kappa opioid agonists and cocaine. Preclinical studies. Ann N Y Acad Sci (2000) 1.50

Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry (1994) 1.46

The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry (1998) 1.45

Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) (2005) 1.43

Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum. Org Lett (2001) 1.43

Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci (2003) 1.42

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) (2011) 1.36

Human hallucinogen research: guidelines for safety. J Psychopharmacol (2008) 1.33

Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication. AMA Arch Neurol Psychiatry (1956) 1.30

Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev (2011) 1.26

The dynorphin/κ-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci (2011) 1.25

Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci (2005) 1.25

Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend (2010) 1.20

Salvinorin A: from natural product to human therapeutics. Mol Interv (2006) 1.19

The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl) (2003) 1.17

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol (2010) 1.15

Salvia divinorum: effects and use among YouTube users. Drug Alcohol Depend (2009) 1.14

Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend (2010) 1.12

Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav (2009) 1.11

Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry (2007) 1.09

Adolescent salvia substance abuse. Addiction (2007) 1.07

Antidepressant effects of the herb Salvia divinorum: a case report. J Clin Psychopharmacol (2001) 1.06

Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. Psychopharmacology (Berl) (2007) 1.04

Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biol Psychiatry (2012) 1.04

Kappa opioids and the modulation of pain. Psychopharmacology (Berl) (2010) 1.03

Voice of the psychonauts: coping, life purpose, and spirituality in psychedelic drug users. J Psychoactive Drugs (2011) 1.01

Psychedelic drugs and mystical experience. Int Psychiatry Clin (1969) 0.99

Persistent psychosis associated with salvia divinorum use. Am J Psychiatry (2009) 0.96

Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Subst Abuse Rehabil (2011) 0.94

Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther (1986) 0.93

Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology (Berl) (2011) 0.91

Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl) (2007) 0.90

Salvia divinorum use and phenomenology: results from an online survey. J Psychopharmacol (2010) 0.89

Toxic psychosis after intake of the hallucinogen salvinorin A. J Clin Psychiatry (2008) 0.86

High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology (Berl) (2012) 0.85

Subjective effects of Salvia divinorum: LSD- or marijuana-like? J Psychoactive Drugs (2009) 0.84

Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug Alcohol Depend (2010) 0.82

Use of Salvia divinorum in a nationally representative sample. Am J Drug Alcohol Abuse (2011) 0.82

Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial. Psychopharmacology (Berl) (2010) 0.80

Legally tripping: a qualitative profile of Salvia divinorum use among young adults. J Psychoactive Drugs (2011) 0.78

Caffeinated energy drinks--a growing problem. Drug Alcohol Depend (2008) 4.98

Delay discounting in current and never-before cigarette smokers: similarities and differences across commodity, sign, and magnitude. J Abnorm Psychol (2003) 3.76

Energy drink consumption and increased risk for alcohol dependence. Alcohol Clin Exp Res (2010) 3.14

Delay discounting in currently using and currently abstinent cocaine-dependent outpatients and non-drug-using matched controls. Addict Behav (2005) 2.22

Increased alcohol consumption, nonmedical prescription drug use, and illicit drug use are associated with energy drink consumption among college students. J Addict Med (2010) 2.19

Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J Med Chem (2005) 2.13

Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend (2009) 2.03

Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther (2009) 1.88

A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl) (2004) 1.81

The behavioral economics of substance use disorders: reinforcement pathologies and their repair. Annu Rev Clin Psychol (2014) 1.74

Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend (2003) 1.71

The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing. Ann Surg (2010) 1.69

A facile method for the preparation of deuterium labeled salvinorin A: synthesis of [2,2,2-2H3]-salvinorin A. Bioorg Med Chem Lett (2004) 1.60

Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology (Berl) (2009) 1.60

Synthetic studies of neoclerodane diterpenoids from Salvia splendens and evaluation of Opioid Receptor affinity. Tetrahedron (2008) 1.53

Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology (Berl) (2014) 1.48

Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry (2005) 1.48

Synthesis of salvinorin A analogues as opioid receptor probes. J Nat Prod (2006) 1.39

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) (2011) 1.36

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A. J Nat Prod (2006) 1.36

Reactive oxygen and targeted antioxidant administration in endothelial cell mitochondria. J Biol Chem (2006) 1.35

The behavioral pharmacology of hallucinogens. Biochem Pharmacol (2007) 1.35

Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol (2012) 1.32

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ring. Bioorg Med Chem Lett (2006) 1.29

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol (2011) 1.27

Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev (2011) 1.26

A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse (2007) 1.24

Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum. Org Lett (2005) 1.23

Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry (2006) 1.22

Salvinorin A: allosteric interactions at the mu-opioid receptor. J Pharmacol Exp Ther (2006) 1.21

Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend (2010) 1.20

Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol (2007) 1.20

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. J Med Chem (2007) 1.18

Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem (2013) 1.17

Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend (2009) 1.17

Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin. J Sci Study Relig (2012) 1.16

Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology (2006) 1.16

THE EFFECTS OF REDUCED CIGARETTE SMOKING ON DISCOUNTING FUTURE REWARDS: AN INITIAL EVALUATION. Psychol Rec (2008) 1.16

Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synapse (2005) 1.13

Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. J Pharmacol Exp Ther (2006) 1.12

Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther (2008) 1.12

R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry (2012) 1.12

Oral caffeine maintenance potentiates the reinforcing and stimulant subjective effects of intravenous nicotine in cigarette smokers. Psychopharmacology (Berl) (2002) 1.11

Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav (2009) 1.11

Relationship between cooperation in an iterated prisoner's dilemma game and the discounting of hypothetical outcomes. Learn Behav (2005) 1.07

Celiac disease: management of persistent symptoms in patients on a gluten-free diet. World J Gastroenterol (2012) 1.07

Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J Med Chem (2008) 1.07

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position. Bioorg Med Chem Lett (2007) 1.07

Effects of varenicline on abstinence and smoking reward following a programmed lapse. Nicotine Tob Res (2012) 1.05

Dose effects of triazolam and alcohol on cognitive performance in healthy volunteers. Exp Clin Psychopharmacol (2010) 1.05

Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem (2008) 1.03

Kappa opioids and the modulation of pain. Psychopharmacology (Berl) (2010) 1.03

Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.01

Uptake, distribution and diffusivity of reactive fluorophores in cells: implications toward target identification. Mol Pharm (2010) 1.00

Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend (2011) 1.00

Opportunity costs of reward delays and the discounting of hypothetical money and cigarettes. J Exp Anal Behav (2014) 0.99

Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys. Exp Clin Psychopharmacol (2010) 0.99

Caffeine dependence in combination with a family history of alcoholism as a predictor of continued use of caffeine during pregnancy. Am J Psychiatry (2005) 0.98

Transdermal nicotine maintenance attenuates the subjective and reinforcing effects of intravenous nicotine, but not cocaine or caffeine, in cigarette-smoking stimulant abusers. Neuropsychopharmacology (2004) 0.98

Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A. Medchemcomm (2011) 0.97

Lorazepam and scopolamine: A single-dose comparison of effects on human memory and attentional processes. Exp Clin Psychopharmacol (2003) 0.97

Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor. Synapse (2010) 0.97

Attenuation of cocaine-seeking by GABA B receptor agonists baclofen and CGP44532 but not the GABA reuptake inhibitor tiagabine in baboons. Drug Alcohol Depend (2007) 0.97

Discovery of a novel selective kappa-opioid receptor agonist using crystal structure-based virtual screening. J Chem Inf Model (2013) 0.96

Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm (2009) 0.96

Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships. J Nat Prod (2007) 0.95

Differential effects of scopolamine and lorazepam on working memory maintenance versus manipulation processes. Cogn Affect Behav Neurosci (2007) 0.94

Effects of GABAergic modulators on food and cocaine self-administration in baboons. Drug Alcohol Depend (2005) 0.93

Drugs, memory, and metamemory: a dose-effect study with lorazepam and scopolamine. Exp Clin Psychopharmacol (2005) 0.93

Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons. Psychopharmacology (Berl) (2005) 0.93

Semisynthetic neoclerodanes as kappa opioid receptor probes. Bioorg Med Chem (2012) 0.93

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev (2014) 0.92

Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. Pharmacol Biochem Behav (2007) 0.92

Opioid receptor probes derived from cycloaddition of the hallucinogen natural product salvinorin A. J Nat Prod (2011) 0.92

A triazolam/amphetamine dose-effect interaction study: dissociation of effects on memory versus arousal. Psychopharmacology (Berl) (2007) 0.92

Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use. Exp Clin Psychopharmacol (2011) 0.91

Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend (2006) 0.91

Characterization of individuals seeking treatment for caffeine dependence. Psychol Addict Behav (2012) 0.91

Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues. ACS Med Chem Lett (2010) 0.91

Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration: cerebral blood flow velocity, quantitative EEG, and subjective effects. Psychopharmacology (Berl) (2009) 0.91

Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults. Exp Clin Psychopharmacol (2006) 0.91

Self-injection of flunitrazepam alone and in the context of methadone maintenance in baboons. Drug Alcohol Depend (2004) 0.90

Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo. J Pharmacol Exp Ther (2012) 0.90

Demand curves for hypothetical cocaine in cocaine-dependent individuals. Psychopharmacology (Berl) (2013) 0.90

Reinstatement of methamphetamine seeking in male and female rats treated with modafinil and allopregnanolone. Drug Alcohol Depend (2011) 0.90

Examining Delay Discounting of Condom-Protected Sex Among Men Who Have Sex with Men Using Crowdsourcing Technology. AIDS Behav (2015) 0.90

Investigation of "bath salts" use patterns within an online sample of users in the United States. J Psychoactive Drugs (2014) 0.90

Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. ACS Chem Neurosci (2012) 0.89

Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors. Brain Res Bull (2008) 0.88

Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons. Psychopharmacology (Berl) (2006) 0.88

Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. Psychopharmacology (Berl) (2014) 0.87

Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend (2011) 0.87

The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects. Psychopharmacology (Berl) (2010) 0.87

Triazolam-amphetamine interaction: dissociation of effects on memory versus arousal. J Psychopharmacol (2003) 0.87

The effects of herkinorin, the first mu-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates. J Pharmacol Exp Ther (2008) 0.86

(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection. J Med Chem (2012) 0.86